You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Patient Characteristics (N = 12)

From: A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma

Characteristic Value
Age at diagnosis – median (range) 66.8 (55.0–85.1)
Male – n (%) 7 (58.3)
Laterality – n (%)
 Left Kidney 4 (33.3)
 Right Kidney 8 (66.7)
Histology – n (%)
 Clear Cell 9 (75)
 Papillary 2 (16.7)
 Othera 1 (8.3)
Location of Metastasesb
 Lung 10 (83.3)
 Bone 6 (50)
 Lymph nodes 5 (41.7)
 Brain 3 (25)
 Otherc 4 (33.3)
Karnofsky Performance Status – median (range) 70 (40–90)
Karnofsky Performance Status – n (%)
 ≥ 80% 5 (41.7)
 <  80% 7 (58.3)
IMDC Prognostic Group – n (%)
 Favorable 1 (8.3)
 Intermediate 8 (66.7)
 Poor 3 (25)
Systemic Therapy Timingb – n (%)  
 None 6 (50)
 Pre-SABR 1 (8.3)
 Post-SABR 4 (33.3)
 Both 1 (8.3)
Systemic Therapy Type – n (%)
 None 6 (50)
 Pazopanib or Sunitinib 5 (41.7)
 Temsirolimus or Everolimus 2 (16.7)
SABR Treatment Technique – n (%)
 VMAT 7 (58.3)
 TOMO 5 (41.7)
Dose Cohort (Gy) – n (%)
 25/5 3 (25)
 30/5 6 (50)
 35/5 3 (25)
Primary tumor sized (cm) – median (range) 8.7 (4.8–13.8)
Actuarial median follow-up (months)e - median (95% CI) 22 (4.63, N/A)
  1. IMDC: International Metastatic Renal Cell Carcinoma Database Consortium, SABR: stereotactic ablative radiotherapy, CI: confidence interval, TOMO: helical tomotherapy, IMRT: intensity modulated radiotherap. aPoorly-differentiated carcinoma (n = 1); bCategories not mutually-exclusive; cKidney (n = 1), liver (n = 2), left adrenal (n = 1); dLongest tumor dimension on CT scan; eReverse Kaplan-Meier Method